Victoza liraglutide regulatory update

Novo Nordisk said FDA approved an updated label for Victoza liraglutide to include the use of the Type II diabetes drug in combination therapy with basal insulin and to include efficacy data when compared to Januvia sitagliptin. In a 26-week, open-label Phase III trial, 1.2 and 1.8 mg once-daily subcutaneous Victoza led to significantly greater reductions in HbA1c vs. 100 mg once-daily Januvia (1.2% and 1.5%, respectively, vs. 0.9%, p<0.0001 for both). Low- and high-dose Victoza also led to greater weight loss (2.7 and 3.3 kg, respectively, vs. 0.8 kg). ...